Identification of essential genes for cancer immunotherapy

Nature

Volumn 548, Issue 7669, 2017, Pages 537-542

  Patel, Shashank J ^a,b   Sanjana, Neville E ^c,d   Kishton, Rigel J ^a   Eidizadeh, Arash ^a   Vodnala, Suman K ^a   Cam, Maggie ^a   Gartner, Jared J ^a   Jia, Li ^a   Steinberg, Seth M ^a   Yamamoto, Tori N ^a,e   Merchant, Anand S ^a   Mehta, Gautam U ^a   Chichura, Anna ^a   Shalem, Ophir ^e   Tran, Eric ^a   Eil, Robert ^a   Sukumar, Madhusudhanan ^a   Guijarro, Eva Perez ^a   Day, Chi Ping ^a   Robbins, Paul ^a   Feldman, Steve ^a   Merlino, Glenn ^a   Zhang, Feng ^f,g   Restifo, Nicholas P ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK GENOME CENTER   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN RECEPTOR; GAMMA INTERFERON; JANUS KINASE 1; TUMOR ANTIGEN; APELIN; HLA ANTIGEN CLASS 1; JAK1 PROTEIN, HUMAN;

ANTIGEN; CANCER; GENE EXPRESSION; GENOMICS; IDENTIFICATION METHOD; IMMUNE RESPONSE; IMMUNE SYSTEM; MUTATION; NUMERICAL MODEL; TUMOR; VULNERABILITY;

ANTIGEN PRESENTATION; ARTICLE; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL TRANSFER; CRISPR-CAS9 SYSTEM; CYTOLOGY; GENE FUNCTION; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MELANOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; ADOPTIVE TRANSFER; ANIMAL; CRISPR CAS SYSTEM; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; ESSENTIAL GENE; FEMALE; GENETICS; GENOME; IMMUNOLOGY; IMMUNOTHERAPY; KNOWLEDGE BASE; MELANOMA; METABOLISM; MOUSE; MUTATION; NEOPLASM; REPRODUCIBILITY; SECRETION (PROCESS); TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; APELIN; APELIN RECEPTORS; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; FEMALE; GENES, ESSENTIAL; GENOME; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; JANUS KINASE 1; KNOWLEDGE BASES; MELANOMA; MICE; MUTATION; NEOPLASMS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85028707868     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23477     Document Type: Article

References (49)

1. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013).
2. Chan, T. A., Wolchok, J. D. & Snyder, A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 373, 1984 (2015).
3. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
4. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016).
5. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
6. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387-1390 (2015).
7. Le, D. T. et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science aan6733 (2017).
8. Restifo, N. P. et al. Loss of functional ? 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88, 100-108 (1996).
9. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
10. Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096-1101 (2015).
11. Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515-1526 (2015).
12. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
13. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
14. Chen, S. et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246-1260 (2015).
15. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
16. Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6, 254ra128 (2014).
17. Robbins, P. F. et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116-6131 (2008).
18. Johnson, L. A. et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177, 6548-6559 (2006).
19. Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019-1027 (2015).
20. Spiotto, M. T., Rowley, D. A. & Schreiber, H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10, 294-298 (2004).
21. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
22. Luo, B. et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl Acad. Sci. USA 105, 20380-20385 (2008).
23. Indraccolo, S. et al. Identification of genes selectively regulated by IFNs in endothelial cells. J. Immunol. 178, 1122-1135 (2007).
24. Sanda, C. et al. Differential gene induction by type I and type II interferons and their combination. J. Interferon Cytokine Res. 26, 462-472 (2006).
25. Viemann, D. et al. TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells. J. Leukoc. Biol. 80, 174-185 (2006).
26. Klijn, C. et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33, 306-312 (2015).
27. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
28. Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, aah3560 (2017).
29. Nathanson, T. et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol. Res. 5, 84-91 (2017).
30. O'Carroll, A.-M., Lolait, S. J., Harris, L. E. & Pope, G. R. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J. Endocrinol. 219, R13-R35 (2013).
31. Stark, C. et al. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535-D539 (2006).
32. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848 (2006).
33. Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003).
34. Wang, L.-X. et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One 8, e62924 (2013).
35. Wrangle, J. et al. Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget 4, 2067-2079 (2013).
36. Marrero, M. B. et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375, 247-250 (1995).
37. Kidoya, H. et al. The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy. Oncogene 31, 3254-3264 (2012).
38. Kammertoens, T. et al. Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature 545, 98-102 (2017).
39. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10-12 (2011).
40. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
41. Wan, Y.-W., Allen, G. I. & Liu, Z. TCGA2STAT: simple TCGA data access for integrated statistical analysis in R. Bioinformatics 32, 952-954 (2016).
42. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
43. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
44. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114-2120 (2014).
45. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
46. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013).
47. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
48. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protocols 7, 562-578 (2012).
49. Noonan, F. P. et al. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat. Commun. 3, 884 (2012).